Literature DB >> 16628670

Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells.

Thomas von Hahn1, Brett D Lindenbach, Agnès Boullier, Oswald Quehenberger, Matthew Paulson, Charles M Rice, Jane A McKeating.   

Abstract

Cell entry of hepatitis C virus, pseudoparticles (HCVpp) and cell culture grown virus (HCVcc), requires the interaction of viral glycoproteins with CD81 and other as yet unknown cellular factors. One of these is likely to be the scavenger receptor class B type I (SR-BI). To further understand the role of SR-BI, we examined the effect of SR-BI ligands on HCVpp and HCVcc infectivity. Oxidized low-density lipoprotein (oxLDL), but not native LDL, potently inhibited HCVpp and HCVcc cell entry. Pseudoparticles bearing unrelated viral glycoproteins or bovine viral diarrhea virus were not affected. A dose-dependent inhibition was observed for HCVpp bearing diverse viral glycoproteins with an approximate IC50 of 1.5 microg/mL apolipoprotein content, which is within the range of oxLDL reported to be present in human plasma. The ability of lipoprotein components to bind to target cells associated with their antiviral activity, suggesting a mechanism of action which targets a cell surface receptor critical for HCV infection of the host cell. However, binding of soluble E2 to SR-BI or CD81 was not affected by oxLDL, suggesting that oxLDL does not act as a simple receptor blocker. At the same time, oxLDL incubation altered the biophysical properties of HCVpp, suggesting a ternary interaction of oxLDL with both virus and target cells. In conclusion, the SR-BI ligand oxLDL is a potent cell entry inhibitor for a broad range of HCV strains in vitro. These findings suggest that SR-BI is an essential component of the cellular HCV receptor complex.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16628670     DOI: 10.1002/hep.21139

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  42 in total

Review 1.  Unique ties between hepatitis C virus replication and intracellular lipids.

Authors:  Eva Herker; Melanie Ott
Journal:  Trends Endocrinol Metab       Date:  2011-04-15       Impact factor: 12.015

Review 2.  Studying hepatitis C virus: making the best of a bad virus.

Authors:  Timothy L Tellinghuisen; Matthew J Evans; Thomas von Hahn; Shihyun You; Charles M Rice
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

3.  HCV entry and neutralizing antibodies: lessons from viral variants.

Authors:  Mirjam B Zeisel; Thomas F Baumert
Journal:  Future Microbiol       Date:  2009-06       Impact factor: 3.165

Review 4.  Mechanisms of HCV survival in the host.

Authors:  Ella H Sklan; Prista Charuworn; Philip S Pang; Jeffrey S Glenn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-04       Impact factor: 46.802

Review 5.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

6.  Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion.

Authors:  Nishi R Sharma; Guaniri Mateu; Marlene Dreux; Arash Grakoui; François-Loïc Cosset; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2011-07-07       Impact factor: 5.157

7.  Interplay among cellular polarization, lipoprotein metabolism and hepatitis C virus entry.

Authors:  Ignacio Benedicto; Francisca Molina-Jiménez; Ricardo Moreno-Otero; Manuel López-Cabrera; Pedro L Majano
Journal:  World J Gastroenterol       Date:  2011-06-14       Impact factor: 5.742

Review 8.  Novel concepts in HDL pharmacology.

Authors:  Alan T Remaley; Giuseppe D Norata; Alberico L Catapano
Journal:  Cardiovasc Res       Date:  2014-06-20       Impact factor: 10.787

9.  Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.

Authors:  Dorothea Bankwitz; Eike Steinmann; Julia Bitzegeio; Sandra Ciesek; Martina Friesland; Eva Herrmann; Mirjam B Zeisel; Thomas F Baumert; Zhen-yong Keck; Steven K H Foung; Eve-Isabelle Pécheur; Thomas Pietschmann
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

10.  Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains.

Authors:  Marlène Dreux; Viet Loan Dao Thi; Judith Fresquet; Maryse Guérin; Zélie Julia; Géraldine Verney; David Durantel; Fabien Zoulim; Dimitri Lavillette; François-Loïc Cosset; Birke Bartosch
Journal:  PLoS Pathog       Date:  2009-02-20       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.